You are viewing an old version of this page. View the current version.

Compare with Current View Page History

Version 1 Next »

Cancer Synoptic Reporting Project Group

07 March 2022 at 17:30 UTC

Attendees Scott Campbell 



Discussion items

ItemDescriptionOwnerNotesAction
1Treatment effect

Continue discussion:

What are we measuring when assessing "treatment effect"?  

Is this a histologic change?  Viability of tumor cells?

  1. Primary site
  2. Lymph node


Note: SSA wonders about property in this model

  1. Primary site



  2. Lymph node


Will review model.  This observable pertains to the process of regression/change in the neoplasm after antineoplastic therapy.  So, observable could be modeled as presence of process changes.

2PatternsScott Campbell
  1. How to handle patterns within histologies
    1. Lung (Lepidic, acinar)
    2. DCIS
    3. Bladder (differentiation)

3Lymph nodes
  1. Discuss approach to lymph node body structures and differences in naming/locations (example AJCC esophageal cancer vs. JES esophageal cancer)

2. Management of observables for lymph node involvement.  Example: 


4AJCC update?Any updates that can be shared?Jim Case meeting with AJCC on Wednesday 26-Jan to continue/finalize contract issues

Meeting Files

No files shared here yet.




Previous Meetings

TitleCreatorModified
No content found.

  • No labels